Optimized Cationic Lipid-assisted Nanoparticle for Delivering CpG Oligodeoxynucleotides to Treat Hepatitis B Virus Infection

Yi-Fang Chen,Yan Wang,Yue Wang,Ying-Li Luo,Zi-Dong Lu,Xiao-Jiao Du,Cong-Fei Xu,Jun Wang
DOI: https://doi.org/10.1007/s11095-022-03307-w
IF: 4.58
2022-01-01
Pharmaceutical Research
Abstract:Purpose Hepatitis B virus (HBV) infection is such a global health problem that hundreds of millions of people are HBV carriers. Current anti-viral agents can inhibit HBV replication, but can hardly eradicate HBV. Cytosine-phosphate-guanosine (CpG) oligodeoxynucleotides (ODNs) are an adjuvant that can activate plasmacytoid dendritic cells (pDCs) and conventional dendritic cells (cDCs) to induce therapeutic immunity for HBV eradication. However, efficient delivery of CpG ODNs into pDCs and cDCs remains a challenge. In this study, we constructed a series of cationic lipid-assisted nanoparticles (CLANs) using different cationic lipids to screen an optimal nanoparticle for delivering CpG ODNs into pDCs and cDCs. Methods We constructed different CLAN CpG using six cationic lipids and analyzed the cellular uptake of different CLAN CpG by pDCs and cDCs in vitro and in vivo , and further analyzed the efficiency of different CLAN CpG for activating pDCs and cDCs in both wild type mice and HBV-carrier mice. Results We found that CLAN fabricated with 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP) showed the highest efficiency for delivering CpG ODNs into pDCs and cDCs, resulting in strong therapeutic immunity in HBV-carrier mice. By using CLAN CpG as an immune adjuvant in combination with the injection of recombinant hepatitis B surface antigen (rHBsAg), HBV was successfully eradicated and the chronic liver inflammation in HBV-carrier mice was reduced. Conclusion We screened an optimized CLAN fabricated with DOTAP for efficient delivery of CpG ODNs to pDCs and cDCs, which can act as a therapeutic vaccine adjuvant for treating HBV infection.
What problem does this paper attempt to address?